生物制剂在化脓性汗腺炎治疗中的应用进展  

Advances in the Application of Biologic in Hidradenitis Suppurativa

作　　者：王慧 黄贺 张学军[1] 高敏[1] WANG Hui;HUANG He;ZHANG Xuejun;GAO Min(Department of Dermatology,the First Affiliated Hospital of Anhui Medical University,Key Laboratory of Dermatology,Anhui Medical University,Ministry of Education,Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Hefei 230022,China)

机构地区：[1]安徽医科大学皮肤病研究所,安徽医科大学第一附属医院皮肤病与性病科,教育部重点实验室,重大自身免疫性疾病安徽省重点实验室,安徽合肥230022

出　　处：《中国皮肤性病学杂志》2022年第2期218-221,共4页The Chinese Journal of Dermatovenereology

摘　　要：化脓性汗腺炎(hidradenitis suppurativa,HS)是一种病变始发于毛囊的慢性、炎症性皮肤病。随着免疫机制研究进展,靶向生物制剂逐渐应用于该病的治疗。本文回顾了生物制剂在化脓性汗腺炎的应用进展和作用机制,为日后进一步的临床应用提供思路。Hidradenitis Suppurativa(HS)is a chronic and inflammatory skin disorder of hair follicles.With the study of immune pathogenesis,several biologics have been trialed and applied in HS.This paper aims to review the mechanism and application of biological in the treatment of HS,to provide guide for clinical application in the future.

关 键 词：化脓性汗腺炎 生物制剂 

分 类 号：R758.746[医药卫生—皮肤病学与性病学]